Royalty Pharma plcRPRX

時価総額

$227億

PER

バイオ医薬品ロイヤリティ取得の最大手。35超の商業製品ロイヤリティと15療法の年商10億ドル超ポートフォリオ、平均残存期間約13年のロイヤリティを保有。2025年1月にマネジャー買収で約11億ドル合意。米国・欧州中心の世界展開。

	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Cash collections from financial royalty assets	2,122	2,316	2,507	3,201	2,983
Cash collections from intangible royalty assets	144	151	73	1	15
Other royalty cash collections	18	44	70	159	109
Distributions from equity method investees	42	34	39	19	13
Interest received	8	3	25	72	46
Development-stage funding payments - ongoing	20	7	2	2	2
Development-stage funding payments - upfront and milestone	6	193	175	50	-
Payments for operating and professional costs	180	185	223	243	236
Interest paid	103	130	170	169	160
Net cash provided by operating activities	2,035	2,018	2,144	2,988	2,769
Distributions from equity method investees	15	1	-	44	24
Investments in equity method investees	40	35	10	13	11
Purchases of equity securities	50	135	88	-	63
Proceeds from equity securities	385	116	211	-	99
Purchases of available for sale debt securities	-	70	480	-	150
Proceeds from available for sale debt securities	3	63	542	1	20
Purchases of marketable securities	1,705	1,197	235	-	-
Proceeds from Sale and Maturity of Marketable Securities	815	1,598	792	24	-
Acquisitions of financial royalty assets	2,182	2,192	1,742	2,116	2,506
Acquisitions of other financial assets	-	-	21	-	18
Milestone payments	-	19	-	12	75
Other	-	-	-	2	-2
Net cash used in investing activities	-2,759	-1,870	-1,029	-2,073	-2,678
Distributions to legacy non-controlling interests - Portfolio Receipts	-	-	442	377	362
Distributions to legacy non-controlling interests - other	181	154	31	-	-
Distributions to continuing non-controlling interests	544	480	144	120	125
Dividends to shareholders	112	285	333	358	376
Repurchases of Class A ordinary shares	-	-	-	305	230
Contributions from legacy non-controlling interests - R&D	8	7	1	1	1
Proceeds From Noncontrolling Interests, Other	59	37	6	7	4
Cash acquired in connection with purchase of non-controlling interest	-	-	-	5	-
Proceeds from revolving credit facility	-	-	-	350	-
Repayment of revolving credit facility	-	-	-	350	-
Repayment of long-term debt	-	-	-	1,000	-
Proceeds from Issuance of Other Long-Term Debt	-	-	-	-	1,471
Debt issuance costs and other	47	13	1	2	13
Other	-	-	-	-	-9
Net cash provided by/(used in) in financing activities	1,487	385	-945	-2,149	361
Net change in cash and cash equivalents	762	532	170	-1,234	452